New pharmacotherapy for airway mucus hypersecretion in asthma and COPD: Targeting intracellular signaling pathways

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 23, Issue 4, 2010, Pages 219-231

  Lai, Honyee ^a   Rogers, Duncan F ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

chronic bronchitis; epidermal growth factor; goblet cell; IL 13; mucin

Indexed keywords

ADALIMUMAB; BATIMASTAT; CHLORIDE CHANNEL; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ETANERCEPT; GEFITINIB; HEPATOCYTE NUCLEAR FACTOR 3BETA; IMA 638; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 13; INTERLEUKIN 13 ANTIBODY; INTERLEUKIN 19; INTERLEUKIN 1BETA; INTERLEUKIN 4 RECEPTOR ALPHA; INTERLEUKIN 9; MONOCLONAL ANTIBODY; MUCIN; NIFLUMIC ACID; PROTEIN CLCA; SORAFENIB; STAT6 PROTEIN; SURAMIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AIRWAY OBSTRUCTION; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; GENE EXPRESSION; GOBLET CELL; HUMAN; INFLAMMATION; MUCUS SECRETION; NONHUMAN; RESPIRATORY TRACT MUCOSA; REVIEW; SIGNAL TRANSDUCTION; TH2 CELL; UPREGULATION;

ANIMALS; ASTHMA; CYCLOOXYGENASE 2; CYTOKINES; DRUG DELIVERY SYSTEMS; GOBLET CELLS; HUMANS; HYPERPLASIA; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MUCINS; MUCUS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY SYSTEM; SIGNAL TRANSDUCTION;

EID: 77955435635     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2009.0802     Document Type: Review

References (94)

1. Donnelly L, and Rogers D: Novel targets and drugs in inflammatory lung disease. Curr Opin Pharmacol. 2008;8:219-221.
2. Rogers DF: Airway mucus hypersecretion in asthma: an undervalued pathology? Curr Opin Pharmacol. 2004;4:241-250.
3. Rogers DF: Mucoactive agents for airway mucus hypersecretory diseases. Respir Care. 2007;52:1176-1193; discussion 93-97.
4. Rogers DF: Physiology of airway mucus secretion and pathophysiology of hypersecretion. Respir Care. 2007;52: 1134-1146; discussion 46-49.
5. Del Donno M, Bittesnich D, Chetta A, Olivieri D, and Lopez-Vidriero MT: The effect of inflammation on mucociliary clearance in asthma: an overview. Chest. 2000;118:1142-1149.
6. Knowles MR, and Boucher RC: Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest. 2002;109:571-577.
7. Davies JR, Herrmann A, Russell W, Svitacheva N, Wickstrom C, and Carlstedt I: Respiratory tract mucins: structure and expression patterns. Novartis Found Symp. 2002; 248:76-88; discussion, 93, 277-282.
8. Sheehan JK, Thornton DJ, Somerville M, and Carlstedt I: Mucin structure. The structure and heterogeneity of respiratory mucus glycoproteins. Am Rev Respir Dis. 1991;144:S4-S9.
9. Williams OW, Sharafkhaneh A, Kim V, Dickey BF, and Evans CM: Airway mucus: from production to secretion. Am J Respir Cell Mol Biol. 2006;34:527-536.
10. Rose MC, and Voynow JA: Respiratory tract mucin genes and mucin glycoproteins in health and disease. Physiol Rev. 2006;86:245-278.
11. Voynow JA, and Rubin BK: Mucins, mucus, and sputum. Chest. 2009;135:505-512.
12. Thornton DJ, Rousseau K, and McGuckin MA: Structure and function of the polymeric mucins in airways mucus. Annu Rev Physiol. 2008;70:459-486.
13. Ordonez CL, Khashayar R, Wong HH, Ferrando R, Wu R, Hyde DM, Hotchkiss JA, Zhang Y, Novikov A, Dolganov G, and Fahy JV: Mild and moderate asthma is associated with airway goblet cell hyperplasia and abnormalities in mucin gene expression. Am J Respir Crit Care Med. 2001;163:517-523.
14. Jeffery PK: Remodeling in asthma and chronic obstructive lung disease. Am J Respir Crit Care Med. 2001;164:S28-S38.
15. Jeffery PK: Differences and similarities between chronic obstructive pulmonary disease and asthma. Clin Exp Allergy. 1999;29:14-26.
16. Mauad T, and Dolhnikoff M: Pathologic similarities and differences between asthma and chronic obstructive pulmonary disease. Curr Opin Pulmon Med. 2008;14:31-38.
17. Jatakanon A, Vasuf C, Maziak W, Lim S, Chung KF, and Barnes PJ: Neutrophilic inflammation in severe persistent asthma. AM J Respir Crit Care Med. 1999;160:1532-1539.
18. Jeffery PK: Remodeling and inflammation of bronchi in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2004;1:176-183.
19. Fahy JV: Goblet cell and mucin gene abnormalities in asthma. Chest. 2002;122:320S-3206S.
20. Aikawa T, Shimura S, Sasaki H, Ebina M, and Takishima T: Marked goblet cell hyperplasia with mucus accumulation in the airways of patients who died of severe acute asthma attack. Chest. 1992;101:916-921.
21. Rogers DF, and Evans TW: Plasma exudation and oedema in asthma. Br Med Bull. 1992;48:120-134.
22. Bhaskar KR, OSullivan DD, Coles SJ, Kozakewich H, Vawter GP, and Reid LM: Characterization of airway mucus from a fatal case of status asthmaticus. Pediatr Pulmonol. 1988;5:176-182.
23. Sheehan JK, Richardson PS, Fung DC, Howard M, and Thornton DJ: Analysis of respiratory mucus glycoproteins in asthma: a detailed study from a patient who died in status asthmaticus. Am J Respir Cell Mol Biol. 1995;13:748-756.
24. List SJ, Findlay BP, Forstner GG, and Forstner JF: Enhancement of the viscosity of mucin by serum albumin. Biochem J. 1978;175:565-571.
25. Shimura S, Andoh Y, Haraguchi M, and Shirato K: Continuity of airway goblet cells and intraluminal mucus in the airways of patients with bronchial asthma. Eur Respir J. 1996;9:1395-1401.
26. Sutherland ER, and Martin RJ: Airway inflammation in chronic obstructive pulmonary disease: comparisons with asthma. J Allergy Clin Immunol. 2003;112:819-827; quiz 28.
27. Hesselink AE, van der Windt DAWM, Penninx BWJH, Wijnhoven HAH, Twisk JWR, Bouter LM, and van Eijk ThM: What predicts change in pulmonary function and quality of life in asthma or COPD? J Asthma. 2006;43:513-519.
28. Spina D, and Page C: Airway irritability-a burning issue? Curr Opin Pharmacol. 2009;9:530-534.
29. Lai HY, and Rogers DF: Mucus hypersecretion in asthma: intracellular signaling pathways as targets for pharmacotherapy. Curr Opin Allergy Clin Immunol. 2010;10: 67-76.
30. Saetta M, Baraldo S, Corbino L, Turato G, Braccioni F, Rea F, Cavallesco G, Tropeano G, Mapp CE, Maestrelli P, Ciaccia A, and Fabbri LM: CD8ve cells in the lungs of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;160:711-717.
31. Saetta M, Turato G, Baraldo S, Zanin A, Braccioni F, Mapp CE, Maestrelli P, Cavallesco G, Papi A, and Fabbri LM: Goblet cell hyperplasia and epithelial inflammation in peripheral airways of smokers with both symptoms of chronic bronchitis and chronic airflow limitation. Am J Respir Crit Care Med. 2000;161:1016-1021.
32. Innes A, Woodruff P, Ferrando R, Donnelly S, Dolganov GM, Lazarus SC, and Fahy JV: Epithelial mucin stores are increased in the large airways of smokers with airflow obstruction. Chest. 2006;130:1102-1108.
33. Caramori G, Casolari P, Di Gregorio C, Saetta M, Baraldo S, Boschetto P, Ito K, Fabbri LM, Barnes PJ, Adcock IM, Cavallesco G, Chung KF, and Papi A: MUC5AC expression is increased in bronchial submucosal glands of stable COPD patients. Histopathology. 2009;55:321-331.
34. Gynn AA, and Michaels L: Bronchial biopsy in chronic bronchitis and asthma. Thorax. 1960;15:142-153.
35. Finkbeiner WE: Physiology and pathology of tracheobronchial glands. Respir Physiol. 1999;118:77-83.
36. Aikawa T, Shimura S, Sasaki H, Takishima T, Yaegashi H, and Takahashi T: Morphometric analysis of intraluminal mucus in airways in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1989;140:477-482.
37. Lora JM, Zhang DM, Liao SM, Burwell T, King AM, Barker PA, Singh L, Keaveney M, Morgenstern J, Gutiérrez-Ramos JC, Coyle AJ, and Fraser CC: Tumor necrosis factor-a triggers mucus production in airway epithelium through an IkB kinase b-dependent mechanism. J Biol Chem. 2005;280: 36510-36517.
38. Song KS, Lee W-J, Chung KC, Lee WJ, Kim CH, Cho KN, Kang CD, Koo JS, and Yoon JH: Interleukin-1beta and tumor necrosis factor-alpha induce MUC5AC overexpression through a mechanism involving ERK=p38 mitogen-activated protein kinases-MSK1-CREB activation in human airway epithelial cells. J Biol Chem. 2003;278:23243-23250.
39. Atherton HC, Jones G, and Danahay H: IL-13-induced changes in the goblet cell density of human bronchial epithelial cell cultures: MAP kinase and phosphatidylinositol 3- kinase regulation. Am J Physiol Lung Cell Mol Physiol. 2003;285:L730-L739.
40. Vermeer PD, Harson R, Einwalter LA, Moninger T, and Zabner J: Interleukin-9 induces goblet cell hyperplasia during repair of human airway epithelia. Am J Respir Cell Mol Biol. 2003;28:286-295.
41. Whittaker L, Niu N, Temann UA, Stoddard A, Flavell RA, Ray A, Homer RJ, and Cohn L: Interleukin-13 mediates a fundamental pathway for airway epithelial mucus induced by CD4 T cells and interleukin-9. Am J Respir Cell Mol Biol. 2002;27:593-602.
42. Steenwinckel V, Louahed J, Orabona C, Huaux F, Warnier G, McKenzie A, Lison D, Levitt R, and Renauld JC: IL-13 mediates in vivo IL-9 activities on lung epithelial cells but not on hematopoietic cells. J Immunol. 2007;178:3244-3251.
43. Kuperman DA, Huang X, Koth LL, Chang GH, Dolganov GM, Zhu Z, Elias JA, Sheppard D, and Erle DJ: Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma. Nat Med. 2002;8:885-889.
44. Wan H, Kaestner KH, Ang S-L, Kaestner KH, Ang SL, and Whitsett JA: Foxa2 regulates alveolarization and goblet cell hyperplasia. Development. 2004;131:953-964.
45. Chu HW, Balzar S, Seedorf GJ, Westcott JY, Trudeau JB, Silkoff P, and Wenzel SE: Transforming growth factor-beta2 induces bronchial epithelial mucin expression in asthma. Am J Pathol. 2004;165:1097-1106.
46. Nakao I, Kanaji S, Ohta S, Matsushita H, Arima K, Yuyama N, Yamaya M, Nakayama K, Kubo H, Watanabe M, Sagara H, Sugiyama K, Tanaka H, Toda S, Hayashi H, Inoue H, Hoshino T, Shiraki A, Inoue M, Suzuki K, Aizawa H, Okinami S, Nagai H, Hasegawa M, Fukuda T, Green ED, and Izuhara K: Identification of pendrin as a common mediator for mucus production in bronchial asthma and chronic obstructive pulmonary disease. J Immunol. 2008;180:6262-6269.
47. Toda M, Tulic MK, Levitt RC, and Hamid Q: A calciumactivated chloride channel (HCLCA1) is strongly related to IL-9 expression and mucus production in bronchial epithelium of patients with asthma. J Allergy Clin Immunol. 2002;109:246-250.
48. Shim JJ, Dabbagh K, Ueki IF, Ueki IF, Dao-Pick T, Burgel PR, Takeyama K, Tam DC, and Nadel JA: IL-13 induces mucin production by stimulating epidermal growth factor receptors and by activating neutrophils. Am J Physiol Lung Cell Mol Physiol. 2001;280:L134-L140.
49. Chang HY, and Yang X: Proteases for cell suicide: functions and regulation of caspases. Microbiol Mol Biol Rev. 2000;64:821-846.
50. Baud V, and Karin M: Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol. 2001;11:372-377.
51. Hsu H, Shu H-B, Pan M-G, and Goeddel DV: TRADDTRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell. 1996;84:299-308.
52. Delhase M, Hayakawa M, Chen Y, and Karin M: Positive and negative regulation of IkB kinase activity through IKK subunit phosphorylation. Science. 1999;284:309-313.
53. Zhang SQ, Kovalenko A, Cantarella G, and Wallach D: Recruitment of the IKK signalosome to the p55 TNF receptor: RIP and A20 bind to NEMO (IKKgamma) upon receptor stimulation. Immunity. 2000;12:301-311.
54. Li D, Gallup M, Fan N, Szymkowski DE, and Basbaum CB: Cloning of the amino-terminal and 50-flanking region of the human MUC5AC mucin gene and transcriptional upregulation by bacterial exoproducts. J Biol Chem. 1998;273: 6812-6820.
55. Desmet C, Gosset P, Pajak B, Cataldo D, Bentires-Alj M, Lekeux P, and Bureau F: Selective blockade of NFkappa B activity in airway immune cells inhibits the effector phase of experimental asthma. J Immunol. 2004;173:5766-5775.
56. Sousa AR, Lane SJ, Nakhosteen JA, Lee TH, and Poston RN: Expression of interleukin-1 beta (IL-1beta) and interleukin-1 receptor antagonist (IL-1ra) on asthmatic bronchial epithelium. Am J Respir Crit Care Med. 1996;154:1061-1066.
57. Gray T, Nettesheim P, Loftin C, Koo JS, Bonner J, Peddada S, and Langenbach R: Interleukin-1b-induced mucin production in human airway epithelium is mediated bycyclooxygenase-2, prostaglandin E2 receptors, and cyclic AMP-protein kinase A signaling. Mol Pharmacol. 2004;66: 337-346.
58. Kim Y-D, Kwon E-J, Park D-W, Song S-Y, Yoon S-K, and Baek S-H: Interleukin-1beta induces MUC2 and MUC5AC synthesis through cyclooxygenase-2 in NCI-H292 cells. Mol Pharmacol. 2002;62:1112-1118.
59. Umland SP, Schleimer RP, and Johnston SL: Review of the molecular and cellular mechanisms of action of glucocorticoids for use in asthma. Pulmon Pharmacol Ther. 2002;15: 35-50.
60. Park JY, Pillinger MH, and Abramson SB: Prostaglandin E2 synthesis and secretion: the role of PGE2 synthases. Clin Immunol. 2006;119:229-240.
61. Gray T, Coakley R, Hirsh A, Thornton D, Kirkham S, Koo JS, Burch L, Boucher R, and Nettesheim P: Regulation of MUC5AC mucin secretion and airway surface liquid metabolism by IL-1b in human bronchial epithelia. Am J Physiol Lung Cell Mol Physiol. 2004;286:L320-L330.
62. Takeyama K, Fahy JV, and Nadel JA: Relationship of epidermal growth factor receptors to goblet cell production in human bronchi. Am J Respir Crit Care Med. 2001;163:511-516.
63. Hewson CA, Edbrooke MR, and Johnston SL: PMA Induces the MUC5AC respiratory mucin in human bronchial epithelial cells, via PKC, EGF/TGF-alpha, Ras=Raf, MEK, ERK and Sp1-dependent mechanisms. J Mol Biol. 2004;344:683-695.
64. Zhen G, Park SW, Nguyenvu LT, Rodriguez MW, Barbeau R, Paquet AC, and Erle DJ: IL-13 and epidermal growth factor receptor have critical but distinct roles in epithelial cell mucin production. Am J Respir Cell Mol Biol. 2007;36:244-253.
65. Nadel JA, Takeyama K, Dabbagh K, Agust? C, Lausier JA, Ueki IF, Grattan KM, and Nadel JA: Epidermal growth factor system regulates mucin production in airways. Proc Natl Acad Sci USA. 1999;96:3081-3086.
66. Tschumperlin DJ, Dai G, Maly IV, Kikuchi T, Laiho LH, McVittie AK, Haley KJ, Lilly CM, So PT, Lauffenburger DA, Kamm RD, and Drazen JM: Mechanotransduction through growth-factor shedding into the extracellular space. Nature. 2004;429:83-86.
67. Park J-A, and Tschumperlin DJ: Chronic intermittent mechanical stress increases MUC5AC protein expression. Am J Respir Cell Mol Biol. 2009;41:459-466.
68. Weissmann G, Smolen JE, and Korchak HM: Release of inflammatory mediators from stimulated neutrophils. N Engl J Med. 1980;303:27-34.
69. Nadel JA, Takeyama K, Dabbagh K, Jeong Shim J, Dao-Pick T, and Ueki IF: Oxidative stress causes mucin synthesis via transactivation of epidermal growth factor receptor: role of neutrophils. J Immunol. 2000;164:1546-1552.
70. Vivekananda J, Lin A, Coalson JJ, and King RJ: Acute inflammatory injury in the lung precipitated by oxidant stress induces fibroblasts to synthesize and release transforming growth factor-alpha. J Biol Chem. 1994;269:25057-25061.
71. Shao MXG, and Nadel JA: Neutrophil elastase induces MUC5AC mucin production in human airway epithelial cells via a cascade involving protein kinase c, reactive oxygen species, and TNF-alpha converting enzyme. J Immunol. 2005;175:4009-4016.
72. Kohri K, Ueki IF, and Nadel JA: Neutrophil elastase induces mucin production by ligand-dependent epidermal growth factor receptor activation. Am J Physiol Lung Cell Mol Physiol. 2002;283:L531-L540.
73. Deshmukh H, Shaver C, Case L, Dietsch M, Wesselkamper SC, Hardie WD, Korfhagen TR, Corradi M, Nadel JA, Borchers MT, and Leikauf GD: Acrolein-activated matrix metalloproteinase 9 contributes to persistent mucin production. Am J Respir Cell Mol Biol. 2008;38:446-454.
74. Deshmukh HS, McLachlan A, Atkinson JJ, Hardie WD, Korfhagen TR, Dietsch M, Liu Y, Di PY, Wesselkamper SC, Borchers MT, and Leikauf GD: Matrix metalloproteinase-14 mediates a phenotypic shift in the airways to increase mucin production. Am J Respir Crit Care Med. 2009;180:834-845.
75. Hauber H, Hamid Q, Bergeron C, Wallaert B, Olivenstein R, Holroyd KJ, Levitt RC, and Hamid Q: Increased expression of the calcium-activated chloride channel in hCLCA1 in airways of patients with obstructive chronic bronchitis. Can Respir J. 2005;12:143-146.
76. Hauber H-P, Manoukian J, Nguyen LHP, Sobol SE, Levitt RC, Holroyd KJ, McElvaney NG, Griffin S, and Hamid Q: Increased expression of interleukin-9, interleukin-9 receptor, and the calcium-activated chloride channel hCLCA1 in the upper airways of patients with cystic fibrosis. Laryngoscope. 2003;113:1037-1042.
77. Zhou Y, Shapiro M, Dong Q, Louahed J, Weiss C, Wan S, Chen Q, Dragwa C, Savio D, Huang M, Fuller C, Tomer Y, Nicolaides NC, McLane M, and Levitt RC: A calciumactivated chloride channel blocker inhibits goblet cell metaplasia and mucus overproduction. Novartis Found Symp. 2002;248:150-165; discussion 65-70, 277-282.
78. Zhou Y, Dong Q, Louahed J, Dragwa C, Savio D, Huang M, Weiss C, Tomer Y, McLane MP, Nicolaides NC, and Levitt RC: Characterization of a calcium-activated chloride channel as a shared target of Th2 cytokine pathways and its potential involvement in asthma. Am J Respir Cell Mol Biol. 2001; 25:486-491.
79. Nakanishi A, Morita S, Iwashita H, Sagiya Y, Ashida Y, Shirafuji H, Fujisawa Y, Nishimura O, and Fujino M: Role of gob-5 in mucus overproduction and airway hyperresponsiveness in asthma. Proc Natl Acad Sci USA 2001;98:5175-5180.
80. Knight D. Talniflumate (Genaera). Curr Opin Invest Drugs. 2004;5:557-562.
81. Hauber HP, Goldmann T, Vollmer E, Wollenberg B, Hung HL, Levitt RC, and Zabel P: LPS-induced mucin expression in human sinus mucosa can be attenuated by hCLCA inhibitors. J Endotoxin Res. 2007;13:109-116.
82. Robichaud A, Tuck SA, Kargman S, Tam J, Wong E, Abramovitz M, Mortimer JR, Burston HE, Masson P, Hirota J, Slipetz D, Kennedy B, ONeill G, and Xanthoudakis S: Gob-5 is not essential for mucus overproduction in preclinical murine models of allergic asthma. Am J Respir Cell Mol Biol. 2005;33:303-314.
83. Burgel PR, and Nadel JA: Roles of epidermal growth factor receptor activation in epithelial cell repair and mucin production in airway epithelium. Thorax. 2004;59:992-996.
84. Raymond E, Faivre S, and Armand JP: Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs. 2000;60(Suppl 1):15-23.
85. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, and Lynch M: Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008;7:3129-3140.
86. Woodruff PG, Wolff M, Hohlfeld JM, Krug N, Dransfield MT, Sutherland ER, Criner GJ, Kim V, Prasse A, Nivens MC, Tetzlaff K, Heiker R, and Fahy JV: Safety and efficacy of aninhaled epidermal growth factor receptor inhibitor (BIBW2948 BS) in COPD. Am J Respir Crit Care Med. 2010;181:438-445.
87. Karras JG, Crosby JR, Guha M, Tung D, Miller DA, Gaarde WA, Geary RS, Monia BP, and Gregory SA: Antiinflammatory activity of inhaled IL-4 receptor-{alpha} antisense oligonucleotide in mice. Am J Respir Cell Mol Biol. 2007;36:276-285.
88. Henderson WR Jr, Chi EY, Maliszewski CR: Soluble IL-4 receptor inhibits airway inflammation following allergen challenge in a mouse model of asthma. J Immunol. 2000;164: 1086-1095.
89. Blanchard C, Mishra A, Saito-Akei H, Monk P, Anderson I, and Rothenberg ME: Inhibition of human interleukin-13- induced respiratory and oesophageal inflammation by antihuman- interleukin-13 antibody (CAT-354). Clin Exp Allergy. 2005;35:1096-1103.
90. Kasaian MT, Donaldson DD, Tchistiakova L, Marquette K, Tan XY, Ahmed A, Jacobson BA, Widom A, Cook TA, Xu X, Barry AB, Goldman SJ, and Abraham WM: Efficacy of IL-13 neutralization in a sheep model of experimental asthma. Am J Respir Cell Mol Biol 2007;36:368-376.
91. Kinyanjui MW, and Fixman ED: Cell-penetrating peptides and proteins: new inhibitors of allergic airways disease. Can J Physiol Pharmacol. 2008;86:1-7.
92. McCusker CT, Wang Y, Shan J, Kinyanjui MW, Villeneuve A, Michael H, and Fixman ED: Inhibition of experimental allergic airways disease by local application of a cellpenetrating dominant-negative STAT-6 peptide. J Immunol. 2007;179:2556-2564.
93. Mora AL, LaVoy J, McKean M, Stecenko A, Brigham KL, Parker R, and Rojas M: Prevention of NF-kappaB activation in vivo by a cell-permeable NF-kappaB inhibitor peptide. Am J Physiol Lung Cell Mol Physiol. 2005;289:L536-L544.
94. Brightling C, Berry M, and Amrani Y: Targeting TNF-[alpha]: a novel therapeutic approach for asthma. J Allergy Clin Immunol. 2008;121:5-10.